kcc-009 and Liver-Diseases

kcc-009 has been researched along with Liver-Diseases* in 1 studies

Other Studies

1 other study(ies) available for kcc-009 and Liver-Diseases

Article	Year
Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation. FEBS letters, 2006, Apr-17, Volume: 580, Issue:9 Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting MB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation. Topics: Animals; Cell Size; Chemical and Drug Induced Liver Injury; Dicarbethoxydihydrocollidine; Enzyme Inhibitors; GTP-Binding Proteins; Hepatomegaly; Humans; Inclusion Bodies; Isoxazoles; Keratins; Liver Diseases; Mice; Mice, Inbred C3H; Protein Glutamine gamma Glutamyltransferase 2; Proteins; Transglutaminases	2006

Article

Year

Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation.

FEBS letters, 2006, Apr-17, Volume: 580, Issue:9

Mallory bodies (MBs) are characteristic of several liver disorders, and consist primarily of keratins with transglutaminase-generated keratin crosslinks. We tested the effect of the transglutaminase-2 (TG2) inhibitor KCC009 on MB formation in a mouse model fed 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC). KCC009 decreased DDC-induced liver enlargement without affecting MB formation or extent of liver injury. TG2 protein and activity increased after DDC feeding and localized within and outside hepatocytes. KCC009 inhibited DDC-induced hepatomegaly by affecting hepatocyte cell size rather than proliferation. Hence, TG2 is a potential mediator of injury-induced hepatomegaly via modulation of hepatocyte hypertrophy, and KCC009-mediated TG2 inhibition does not affect mouse MB formation.

Topics: Animals; Cell Size; Chemical and Drug Induced Liver Injury; Dicarbethoxydihydrocollidine; Enzyme Inhibitors; GTP-Binding Proteins; Hepatomegaly; Humans; Inclusion Bodies; Isoxazoles; Keratins; Liver Diseases; Mice; Mice, Inbred C3H; Protein Glutamine gamma Glutamyltransferase 2; Proteins; Transglutaminases

2006